Conjugated antibodies are indispensable tools for research, diagnostics, and therapeutics. They span from fluorescently labelled antibodies for imaging, to bi-specific antibodies for dual targeting, and antibody-drug conjugates (ADRs) for selective delivery of cytotoxic agents. Two major challenges are the heterogeneity of conjugated antibodies, and their immunogenicity when used therapeutically. To address these issues, I am currently developing a novel method for site-directed antibody conjugation using a non-immunogenic small protein tag.
I studied Clinical Pharmacy at the Suez Canal University, Egypt and obtained my Masters’ degree in Molecular Pharmacology at the VU University Amsterdam, The Netherlands. In 2014, I joined the Chemical Biology lab of Huib Ovaa at the Netherlands Cancer Institute, where I did my final internship investigating ubiquitin binding domains. After completion of my master studies, I joined the Ovaa group as a technician, and in 2016 I started my PhD focusing on multivalent and bi-specific antibody fragments.